↓ Skip to main content

Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood

Overview of attention for article published in Journal of Translational Medicine, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs
1 blog
twitter
2 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood
Published in
Journal of Translational Medicine, May 2015
DOI 10.1186/s12967-015-0515-z
Pubmed ID
Authors

Lorea Beloki, Miriam Ciaurriz, Cristina Mansilla, Amaya Zabalza, Estela Perez-Valderrama, Edward R. Samuel, Mark W. Lowdell, Natalia Ramirez, Eduardo Olavarria

Abstract

Adoptive transfer of CMV-specific T cells has shown promising results in preventing pathological effects caused by opportunistic CMV infection in immunocompromised patients following allogeneic hematopoietic stem cell transplantation. The majority of studies have used steady-state leukapheresis for CMV-reactive product manufacture, a collection obtained prior to or months after G-CSF mobilization, but the procurement of this additional sample is often not available in the unrelated donor setting. If the cellular product for adoptive immunotherapy could be generated from the same G-CSF mobilized collection, the problems associated with the additional harvest could be overcome. Despite the tolerogenic effects associated with G-CSF mobilization, recent studies described that CMV-primed T cells generated from mobilized donors remain functional. MHC-multimers are potent tools that allow the rapid production of antigen-specific CTLs. Therefore, in the present study we have assessed the feasibility and efficacy of CMV-specific CTL manufacture from G-CSF mobilized apheresis using MHC-multimers. CMV-specific CTLs can be efficiently isolated from G-CSF mobilized samples with Streptamers and are able to express activation markers and produce cytokines in response to antigenic stimulation. However, this anti-viral functionality is moderately reduced when compared to non-mobilized products. The translation of Streptamer technology for the isolation of anti-viral CTLs from G-CSF mobilized PBMCs into clinical practice would widen the number of patients that could benefit from this therapeutic strategy, although our results need to be taken into consideration before the infusion of antigen-specific T cells obtained from G-CSF mobilized samples.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 6%
Unknown 16 94%

Demographic breakdown

Readers by professional status Count As %
Other 3 18%
Student > Ph. D. Student 3 18%
Researcher 2 12%
Student > Bachelor 2 12%
Librarian 1 6%
Other 2 12%
Unknown 4 24%
Readers by discipline Count As %
Agricultural and Biological Sciences 4 24%
Medicine and Dentistry 3 18%
Nursing and Health Professions 1 6%
Arts and Humanities 1 6%
Immunology and Microbiology 1 6%
Other 3 18%
Unknown 4 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2016.
All research outputs
#3,658,150
of 22,805,349 outputs
Outputs from Journal of Translational Medicine
#590
of 3,991 outputs
Outputs of similar age
#47,588
of 266,611 outputs
Outputs of similar age from Journal of Translational Medicine
#14
of 96 outputs
Altmetric has tracked 22,805,349 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,991 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,611 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.